本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 华东医药股份有限公司（以下简称"公司"）于2025年07月16日召 开公司2025年第一次临时股东大会，选举产生了公司第十一届董事会 代表董事共同组成公司第十一届董事会。同日，公司召开了第十一届 董事会第一次会议，选举产生了第十一届董事会董事长、代表公司执 行公司事务的董事、第十一届董事会各专门委员会成员及召集人，并 聘任新一届高级管理人员。现将具体情况公告如下： 一、董事会换届选举情况 证券代码：000963 证券简称：华东医药 公告编号：2025-071 华东医药股份有限公司 关于公司董事会完成换届选举 暨聘任高级管理人员的公告 （一）第十一届董事会成员 经公司2025年第一次临时股东大会选举，吕梁先生、亢伟女士、 朱飞鹏先生、王旸先生、董嘉波先生、钱宇辰先生当选为公司第十一 届董事会非独立董事，黄简女士、王如伟先生、魏淑珍女士、薛丽香 女士当选为公司第十一届董事会独立董事，与公司职工代表大会选举 产生的职工代表董事朱亮先生共同组成公司第十一届董事会。第十一 届董事会任期自公司股东大会选举通过之日起三年。上述 ...

证券代码：000963 证券简称：华东医药 公告编号：2025-069 华东医药股份有限公司 关于完成第十一届董事会职工代表董事选举的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 根据《公司法》《公司章程》等相关规定，公司于2025年07月16 日召开了公司第六届职工代表大会临时会议，经民主选举，一致同意 选举朱亮先生为公司第十一届董事会职工代表董事。本次选举产生的 职工代表董事与公司2025年第一次临时股东大会选举产生的董事共 同组成公司第十一届董事会，任期至公司第十一届董事会任期届满时 止。 华东医药股份有限公司董事会 2025年07月17日 1 附件： 华东医药股份有限公司 第十一届董事会职工代表董事简历 朱亮先生，1977年出生，本科学历。历任杭州华东医药集团有限公司工会主 管、工会副主席、工会主席，现任公司党委委员、工会主席。2017年4月至2019 年6月担任本公司监事。2019年6月至今担任本公司董事，2025年7月16日起担任 本公司职工代表董事。 截至目前，朱亮先生持有公司股票30,000股，与公司控股股东和实际控制人 ——中国远大集 ...

华东医药股份有限公司 证券代码：000963 证券简称：华东医药 公告编号：2025-071 关于公司董事会完成换届选举 暨聘任高级管理人员的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 华东医药股份有限公司（以下简称"公司"）于2025年07月16日召 开公司2025年第一次临时股东大会，选举产生了公司第十一届董事会 6名非独立董事、4名独立董事，与职工代表大会选举产生的1名职工 代表董事共同组成公司第十一届董事会。同日，公司召开了第十一届 董事会第一次会议，选举产生了第十一届董事会董事长、代表公司执 行公司事务的董事、第十一届董事会各专门委员会成员及召集人，并 聘任新一届高级管理人员。现将具体情况公告如下： 一、董事会换届选举情况 （一）第十一届董事会成员 经公司2025年第一次临时股东大会选举，吕梁先生、亢伟女士、 朱飞鹏先生、王旸先生、董嘉波先生、钱宇辰先生当选为公司第十一 届董事会非独立董事，黄简女士、王如伟先生、魏淑珍女士、薛丽香 女士当选为公司第十一届董事会独立董事，与公司职工代表大会选举 产生的职工代表董事朱亮先生共同组成公司第十一届董 ...

证券代码：000963 证券简称：华东医药 公告编号：2025-072 华东医药股份有限公司 关于回购注销部分限制性股票减少注册资本 暨通知债权人的公告 公司债权人可持证明债权债务关系存在的合同、协议及其他有效 凭证的原件及复印件到公司申报债权。债权人为法人的，需同时携带 法人营业执照副本原件及复印件、法定代表人身份证明文件；委托他 人申报的，除上述文件外，还需携带法定代表人授权委托书和代理人 有效身份证件的原件及复印件。债权人为自然人的，需同时携带有效 身份证件的原件及复印件；委托他人申报的，除上述文件外，还需携 带授权委托书和代理人有效身份证件的原件及复印件。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、通知债权人的原因 华东医药股份有限公司（以下简称"公司"）于2025年06月27日召 开的第十届董事会第三十四次会议、第十届监事会第二十四次会议审 议通过了《关于回购注销部分限制性股票并减少公司注册资本的议 案》，并于2025年07月16日召开2025年第一次临时股东大会，审议通 过了《关于回购注销部分限制性股票并减少公司注册资本的议案》， 对首次 ...

2025年第一次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会无否决提案情形，也不涉及变更以往股东大会 已通过决议的情形； 证券代码：000963 证券简称：华东医药 公告编号：2025-068 华东医药股份有限公司 2、本次股东大会对中小股东单独计票。中小股东是指：除公司 董事、监事、高级管理人员以及单独或合计持有公司5%以上股份的股 东以外的其他股东。 一、会议召开情况 1、召开时间：2025年07月16日（星期三）下午14:00-15:00 2、召开地点：浙江省杭州市拱墅区莫干山路858号华东医药股份 有限公司新大楼3楼三潭印月会议室。 3、召开方式：现场投票与网络投票相结合的表决方式 4、召集人：公司董事会 5、主持人：公司董事长 吕梁 6、本次会议召集、召开与表决程序符合《公司法》《深圳证券交 易所股票上市规则》及《公司章程》等法律、法规及规范性文件的规 定。 二、会议出席情况 1、股东出席的总体情况： 通过现场和网络投票的股东799人，代表股份1,153,814,388股，占 公司有表决权股份总数 ...

法律意见书 浙江天册律师事务所 关于 华东医药股份有限公司 2025 年第一次临时股东大会的 法律意见书 浙江省杭州市杭大路 1 号黄龙世纪广场 A 座 11 楼 310007 电话：0571-87901111 传真：0571-87901500 法律意见书 浙江天册律师事务所 关于华东医药股份有限公司 2025 年第一次临时股东大会的 法律意见书 编号：TCYJS2025H1143 号 致：华东医药股份有限公司 浙江天册律师事务所（以下简称"本所"）接受华东医药股份有限公司（以下 简称"华东医药"或"公司"）的委托，指派本所律师参加公司 2025 年第一次临时 股东大会，并根据《中华人民共和国证券法》（以下简称"《证券法》"）、《中 华人民共和国公司法》（以下简称"《公司法》"）和《上市公司股东会规则》（以 下简称"《股东会规则》"）等法律、法规和其他有关规范性文件的要求出具本法 律意见书。 在本法律意见书中，本所律师仅对本次股东大会召集、召开程序、出席人员的 资格、召集人的资格、表决程序及表决结果的合法有效性发表意见，不对会议所审 议的议案内容和该等议案中所表述的事实或数据的真实性和准确性发表意见。 本法律 ...

证券代码：000963 证券简称：华东医药 公告编号：2025-070 华东医药股份有限公司 第十一届董事会第一次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 华东医药股份有限公司（以下简称"公司"）第十一届董事会第 一次会议的通知于2025年07月16日以电话、口头等方式送达各位董事， 于2025年07月16日（星期三）在公司会议室以现场结合通讯方式召开。 经公司全体董事一致同意，豁免本次董事会会议提前通知时限的要求。 会议应参加董事11名，实际参加董事11名。会议由公司董事长主持。 会议的召开和表决程序符合《公司法》《公司章程》的有关规定，会 议合法有效。 二、董事会会议审议情况 董事会就以下议案进行了审议，经书面和通讯方式表决，通过决 议如下： （一）审议通过《关于选举第十一届董事会董事长、代表公司执 行公司事务的董事的议案》 经本次董事会与会董事表决，一致同意选举吕梁先生为公司第十 一届董事会董事长、代表公司执行公司事务的董事，为公司法定代表 人，任期自董事会审议通过之日起，至公司第十一届董事会任期届满 之日止（ ...

Market Overview - A-shares maintained a narrow fluctuation on July 16, with the Shanghai Composite Index closing at 3503.78 points, down 0.03% [1] - The Shenzhen Component Index and the ChiNext Index both fell by 0.22% to 10720.81 points and 2230.19 points, respectively [1] - The total trading volume in the Shanghai and Shenzhen markets was 146.19 billion yuan, a decrease of over 170 billion yuan from the previous day [1] Sector Performance - Financial stocks collectively declined, while the steel, non-ferrous metals, and coal sectors showed weakness [1] - The automotive supply chain stocks surged, with companies like Rongtai Co., Fuda Co., and Zhejiang Rongtai hitting the daily limit [1] - The innovative drug concept saw significant activity, with stocks like Guosheng Tang and Iwu Biotech rising approximately 16% [5][6] - The humanoid robot concept remained hot, with companies like Shangwei New Materials achieving a six-day limit increase [2][4] Notable Company Movements - Huadian New Energy, which debuted on the Shanghai main board, closed up 125.8%, reaching a market value of over 300 billion yuan at one point [1] - Weiyali, a Hong Kong-based electronic component distributor, saw its stock surge by 288% upon resuming trading, with an intraday increase exceeding 900% [1] Humanoid Robot Sector Insights - The humanoid robot industry is in its early stages, with significant growth expected in the next 3 to 5 years across various applications [4] - The current phase is described as the "dawn" of humanoid robot industrialization, with mass production and large-scale application becoming feasible [4] - Cost reduction is crucial for the widespread adoption of humanoid robots, and companies that master core component technologies are recommended for investment [4] Innovative Drug Sector Insights - The innovative drug sector experienced strong gains, with several companies hitting the daily limit [5][6] - The recent launch of the 11th batch of national drug centralized procurement is expected to impact the market, focusing on mature "old drugs" rather than innovative drugs [7] - The introduction of measures to support the high-quality development of innovative drugs indicates a growing role for commercial insurance in the healthcare system [7] Pet Economy Sector Insights - The pet economy concept gained traction, with companies like Weike Technology rising over 10% [8] - The pet food sector is viewed as a growing market with significant long-term growth potential, particularly for domestic brands [8]

Core Viewpoint - The patent battle over the antithrombotic drug Indobufen tablets is intensifying, with multiple companies facing procurement qualification suspensions due to patent disputes [1][2][3]. Patent Dispute Overview - The Zhejiang Provincial Hangzhou Intermediate People's Court has suspended the procurement qualifications of several companies producing Indobufen tablets, including Hunan Shangzhonghe Biological Pharmaceutical Co., Ltd. and Zhejiang Saime Pharmaceutical Co., Ltd. [1][2] - A total of five companies have had their sales of Indobufen tablets suspended, indicating a significant impact on the market [1][8]. Market Potential - Indobufen tablets are becoming a "billion-level" product in the cardiovascular medication sector, with sales in hospitals increasing from 745 million yuan in 2021 to 1.408 billion yuan in 2023, reflecting a compound annual growth rate of 37.4% [3]. - Retail sales also exceeded 100 million yuan in 2023, showcasing strong market demand [3]. Patent Strategy and Challenges - The core of the patent dispute revolves around crystal form patents, which are often used by original drug companies to extend their market exclusivity after the expiration of the basic compound patent [4][5]. - Companies like Huadong Medicine have filed administrative decisions or lawsuits against 15 enterprises for alleged patent infringements, indicating a proactive approach to protect their intellectual property [2][5]. Regulatory Environment - The introduction of the "drug patent linkage system" in 2021 has changed the landscape of pharmaceutical patent protection in China, balancing the needs of original drug innovation and market access for generic drugs [9]. - Companies must ensure they do not infringe on patents to participate in drug procurement, as seen with Guangdong Dongyangguang's suspension due to patent issues [7]. Competitive Landscape - The competition among generic drug companies has shifted from breaking through barriers to building their own barriers through secondary patents, resembling the strategies of original drug companies [9][11]. - The ongoing patent disputes are not limited to Indobufen; other drugs like Benazepril have also faced similar challenges, indicating a broader trend in the industry [10]. Implications for Innovation - The focus on patent strategies may lead to increased investment in research and development among generic drug companies, pushing for innovation in crystal forms and formulation processes [10][11]. - However, the reliance on patent battles could hinder overall industry innovation and delay the reduction of drug prices, contradicting the goals of drug procurement policies aimed at improving accessibility [11].

Summary of Conference Call Notes Industry or Company Involved - The discussion primarily revolves around the pharmaceutical industry, particularly focusing on the implications of U.S. drug pricing policies and U.S.-China trade negotiations on Chinese pharmaceutical companies and their market opportunities. Core Points and Arguments 1. **Positive Impact of U.S.-China Negotiations on Pharmaceuticals** The recent U.S.-China negotiations are viewed as a significant positive for the pharmaceutical sector, alleviating previous concerns regarding trade impacts on drug pricing and exports of innovative drugs and raw materials [1] 2. **U.S. Drug Pricing Policy Changes** Trump's announcement of an executive order to reduce prescription drug prices by 30% to 80% is highlighted. The U.S. drug pricing system, characterized by high list prices, is under scrutiny, with the potential for significant price reductions impacting the market [2][3] 3. **Global Drug Pricing Context** U.S. drug prices are noted to be among the highest globally, particularly for innovative drugs, which are approximately 300% higher than prices in countries like Japan and Germany. This pricing structure encourages innovation but also raises concerns about affordability [3] 4. **Encouragement of Competition** The U.S. policy aims to accelerate competition among high-priced drugs, encouraging the entry of biosimilars and generic drugs, which could benefit Chinese pharmaceutical companies that can offer lower-cost alternatives [4][6] 5. **Opportunities for Chinese Pharmaceutical Companies** The reduction in U.S. drug prices is expected to create opportunities for Chinese companies, particularly in the fast-follow and biosimilar segments, as they can provide high-quality, cost-effective alternatives [6][8] 6. **Long-term Trends Favoring Chinese Innovation** The inefficiencies in innovation among multinational pharmaceutical companies may lead to increased reliance on Chinese innovation and manufacturing capabilities, especially if U.S. companies face cost pressures [7][8] 7. **Market Dynamics and Export Opportunities** The easing of trade tensions is anticipated to enhance the macroeconomic environment in China, leading to improved domestic demand and potential export opportunities for medical devices and raw materials [10][9] 8. **Impact of Drug Price Reductions on Market Dynamics** The anticipated drug price reductions in the U.S. are not expected to significantly diminish the addressable market for Chinese companies, as their market share in the U.S. remains relatively small [11][12] 9. **Long-term Supply Chain Considerations** U.S. concerns regarding supply chain security may lead to a push for domestic manufacturing, which could have long-term implications for Chinese companies seeking to penetrate the U.S. market [14][15] 10. **Investment Recommendations** The call suggests focusing on three categories of companies: innovative leaders, those with strong business development (BD) expectations, and upstream suppliers with global advantages, as the market enters a new growth cycle [16][18] Other Important but Possibly Overlooked Content 1. **Sector-Specific Insights** The discussion includes insights into specific companies and their competitive advantages, such as the potential for certain drugs to achieve significant market penetration despite pricing pressures [31][33] 2. **Emerging Trends in Medical Devices** The call also touches on the medical device sector, emphasizing the importance of high-end equipment and the potential for growth in home healthcare products, which may offer higher profit margins compared to domestic markets [25][26] 3. **Long-term Growth Projections** There is an optimistic outlook for the pharmaceutical sector, with expectations of a gradual recovery in demand and performance improvements in the coming years, driven by policy support and market dynamics [29][40] 4. **Focus on Innovation and R&D** The emphasis on innovation and the need for companies to adapt to changing market conditions is reiterated, highlighting the importance of R&D in maintaining competitive advantages [19][20] 5. **Market Sentiment and Future Outlook** The overall sentiment is cautiously optimistic, with a belief that the current market conditions present opportunities for growth and investment in the pharmaceutical and medical device sectors [46][47]